EXTENDED - TODAY ONLY: MarketBeat All Access For Just $399 $199 (save 50%)
×
S&P 500   3,957.95 (-0.15%)
DOW   33,843.20 (-0.02%)
QQQ   280.61 (-0.74%)
AAPL   140.84 (-2.34%)
MSFT   240.23 (-0.63%)
META   110.04 (+1.16%)
GOOGL   95.32 (-0.76%)
AMZN   92.48 (-1.56%)
TSLA   180.38 (-1.39%)
NVDA   156.55 (-1.09%)
NIO   10.54 (+4.15%)
BABA   80.03 (+5.47%)
AMD   73.60 (+0.56%)
T   18.94 (+0.64%)
MU   54.95 (-1.43%)
CGC   3.44 (+1.18%)
F   13.74 (+0.07%)
GE   85.68 (+0.25%)
DIS   94.46 (-1.29%)
AMC   7.45 (+1.64%)
PYPL   78.01 (-2.40%)
PFE   49.49 (-0.16%)
NFLX   280.01 (-0.41%)
S&P 500   3,957.95 (-0.15%)
DOW   33,843.20 (-0.02%)
QQQ   280.61 (-0.74%)
AAPL   140.84 (-2.34%)
MSFT   240.23 (-0.63%)
META   110.04 (+1.16%)
GOOGL   95.32 (-0.76%)
AMZN   92.48 (-1.56%)
TSLA   180.38 (-1.39%)
NVDA   156.55 (-1.09%)
NIO   10.54 (+4.15%)
BABA   80.03 (+5.47%)
AMD   73.60 (+0.56%)
T   18.94 (+0.64%)
MU   54.95 (-1.43%)
CGC   3.44 (+1.18%)
F   13.74 (+0.07%)
GE   85.68 (+0.25%)
DIS   94.46 (-1.29%)
AMC   7.45 (+1.64%)
PYPL   78.01 (-2.40%)
PFE   49.49 (-0.16%)
NFLX   280.01 (-0.41%)
S&P 500   3,957.95 (-0.15%)
DOW   33,843.20 (-0.02%)
QQQ   280.61 (-0.74%)
AAPL   140.84 (-2.34%)
MSFT   240.23 (-0.63%)
META   110.04 (+1.16%)
GOOGL   95.32 (-0.76%)
AMZN   92.48 (-1.56%)
TSLA   180.38 (-1.39%)
NVDA   156.55 (-1.09%)
NIO   10.54 (+4.15%)
BABA   80.03 (+5.47%)
AMD   73.60 (+0.56%)
T   18.94 (+0.64%)
MU   54.95 (-1.43%)
CGC   3.44 (+1.18%)
F   13.74 (+0.07%)
GE   85.68 (+0.25%)
DIS   94.46 (-1.29%)
AMC   7.45 (+1.64%)
PYPL   78.01 (-2.40%)
PFE   49.49 (-0.16%)
NFLX   280.01 (-0.41%)
S&P 500   3,957.95 (-0.15%)
DOW   33,843.20 (-0.02%)
QQQ   280.61 (-0.74%)
AAPL   140.84 (-2.34%)
MSFT   240.23 (-0.63%)
META   110.04 (+1.16%)
GOOGL   95.32 (-0.76%)
AMZN   92.48 (-1.56%)
TSLA   180.38 (-1.39%)
NVDA   156.55 (-1.09%)
NIO   10.54 (+4.15%)
BABA   80.03 (+5.47%)
AMD   73.60 (+0.56%)
T   18.94 (+0.64%)
MU   54.95 (-1.43%)
CGC   3.44 (+1.18%)
F   13.74 (+0.07%)
GE   85.68 (+0.25%)
DIS   94.46 (-1.29%)
AMC   7.45 (+1.64%)
PYPL   78.01 (-2.40%)
PFE   49.49 (-0.16%)
NFLX   280.01 (-0.41%)
NASDAQ:AGTC

Applied Genetic Technologies - AGTC Stock Forecast, Price & News

$0.38
+0.01 (+2.67%)
(As of 11/29/2022 12:53 PM ET)
Add
Compare
Today's Range
$0.38
$0.39
50-Day Range
$0.23
$0.42
52-Week Range
$0.23
$2.83
Volume
3,689 shs
Average Volume
945,268 shs
Market Capitalization
$26.04 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$3.00

Applied Genetic Technologies MarketRank™ Forecast

Analyst Rating
Hold
2.25 Rating Score
Upside/​Downside
1,804.8% Upside
$7.33 Price Target
Short Interest
Healthy
2.04% of Shares Sold Short
Dividend Strength
N/A
Sustainability
-0.62
Upright™ Environmental Score
News Sentiment
0.37mentions of Applied Genetic Technologies in the last 14 days
Based on 11 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
N/A

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.43 out of 5 stars

Medical Sector

244th out of 1,038 stocks

Biological Products, Except Diagnostic Industry

37th out of 172 stocks

AGTC stock logo

About Applied Genetic Technologies (NASDAQ:AGTC) Stock

Applied Genetic Technologies Corporation, a clinical-stage biotechnology company, develops transformational genetic therapies for patients suffering from rare and debilitating diseases. Its advanced product candidates include three ophthalmology development programs across two targets, including X-linked retinitis pigmentosa, which is in the Phase 1/2 clinical trials; and achromatopsia that is in Phase 1/2 clinical trials. It is also developing an optogenetic product candidate to treat advanced retinal disease. In addition, the company has initiated one preclinical program in otology; preclinical program in dry age-related macular degeneration; and two preclinical programs in targeting central nervous system disorders, including frontotemporal dementia and amyotrophic lateral sclerosis. It has collaboration agreements with University of Florida; Bionic Sight, Inc.; and Otonomy, Inc. The company was incorporated in 1999 and is headquartered in Alachua, Florida.

Receive AGTC Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Applied Genetic Technologies and its competitors with MarketBeat's FREE daily newsletter.

AGTC Stock News Headlines

Applied Genetic Technologies (NASDAQ: AGTC)
Applied Genetic Technologies Corp
AGTC Announces Proposed Underwritten Public Offering
AGTC Announces Key Appointments to Leadership Team
See More Headlines
Receive AGTC Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Applied Genetic Technologies and its competitors with MarketBeat's FREE daily newsletter.

AGTC Company Calendar

Last Earnings
11/09/2021
Today
11/29/2022
Next Earnings (Estimated)
2/13/2023
Fiscal Year End
6/30/2023

Industry, Sector and Symbol

Industry
Biological products, except diagnostic
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:AGTC
Fax
N/A
Employees
83
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$7.33
High Stock Price Forecast
$16.00
Low Stock Price Forecast
$3.00
Forecasted Upside/Downside
+679.2%
Consensus Rating
Hold
Rating Score (0-4)
2.25
Research Coverage
8 Analysts

Profitability

Net Income
$-68,940,000.00
Pretax Margin
-21,537.54%

Debt

Sales & Book Value

Annual Sales
$320,000.00
Book Value
$0.58 per share

Miscellaneous

Free Float
64,859,000
Market Cap
$26.04 million
Optionable
Optionable
Beta
1.59

Key Executives

  • Ms. Susan B. WasherMs. Susan B. Washer (Age 61)
    Pres, CEO & Director
    Comp: $747.84k
  • Mr. Jonathan I. Lieber M.B.A. (Age 52)
    Chief Financial Officer
    Comp: $533.14k
  • Dr. Susan Schneider M.D. (Age 64)
    Chief Medical Officer
    Comp: $480.32k
  • Dr. Nicholas Muzyczka
    Co-Founder
  • Dr. Barry J. Byrne M.D.
    Ph.D., Co-Founder
  • Dr. William W. Hauswirth
    Co-Founder & Member of Ophthalmology Scientific Advisory Board
  • Dr. Richard Jude Samulski Ph.D.
    Co-Founder
  • Dr. Terence R. Flotte M.D.
    Co-Founder
  • Mr. Gerald Anthony Reynolds
    Chief Accounting Officer, Principal Accounting Officer & Treasurer
  • Dr. Abraham Scaria Ph.D. (Age 63)
    Chief Scientific Officer













AGTC Stock - Frequently Asked Questions

Should I buy or sell Applied Genetic Technologies stock right now?

8 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Applied Genetic Technologies in the last twelve months. There are currently 6 hold ratings and 2 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" AGTC shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in AGTC, but not buy additional shares or sell existing shares.
View AGTC analyst ratings
or view top-rated stocks.

What is Applied Genetic Technologies' stock price forecast for 2023?

8 brokerages have issued 12 month price objectives for Applied Genetic Technologies' shares. Their AGTC share price forecasts range from $3.00 to $16.00. On average, they expect the company's stock price to reach $7.33 in the next twelve months. This suggests a possible upside of 1,855.6% from the stock's current price.
View analysts price targets for AGTC
or view top-rated stocks among Wall Street analysts.

How have AGTC shares performed in 2022?

Applied Genetic Technologies' stock was trading at $1.90 at the beginning of 2022. Since then, AGTC stock has decreased by 80.3% and is now trading at $0.3750.
View the best growth stocks for 2022 here
.

Are investors shorting Applied Genetic Technologies?

Applied Genetic Technologies saw a drop in short interest in the month of November. As of November 15th, there was short interest totaling 1,380,000 shares, a drop of 34.3% from the October 31st total of 2,100,000 shares. Based on an average daily trading volume, of 1,160,000 shares, the short-interest ratio is presently 1.2 days.
View Applied Genetic Technologies' Short Interest
.

When is Applied Genetic Technologies' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Monday, February 13th 2023.
View our AGTC earnings forecast
.

How were Applied Genetic Technologies' earnings last quarter?

Applied Genetic Technologies Co. (NASDAQ:AGTC) released its quarterly earnings results on Tuesday, November, 9th. The biotechnology company reported ($0.40) EPS for the quarter, missing analysts' consensus estimates of ($0.35) by $0.05. During the same quarter in the previous year, the business earned ($0.60) EPS.

What other stocks do shareholders of Applied Genetic Technologies own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Applied Genetic Technologies investors own include Sorrento Therapeutics (SRNE), SCYNEXIS (SCYX), Micron Technology (MU), VBI Vaccines (VBIV), Amarin (AMRN), Aldeyra Therapeutics (ALDX), Allena Pharmaceuticals (ALNA), Anavex Life Sciences (AVXL), Galmed Pharmaceuticals (GLMD) and Genocea Biosciences (GNCA).

What is Applied Genetic Technologies' stock symbol?

Applied Genetic Technologies trades on the NASDAQ under the ticker symbol "AGTC."

Who are Applied Genetic Technologies' major shareholders?

Applied Genetic Technologies' stock is owned by a number of institutional and retail investors. Top institutional investors include Vanguard Group Inc. (2.18%), Renaissance Technologies LLC (1.68%), Colony Group LLC (0.65%), Citadel Advisors LLC (0.63%), Virtu Financial LLC (0.17%) and Price T Rowe Associates Inc. MD (0.16%). Insiders that own company stock include Gerald Anthony Reynolds, Patrick Johan Hendrik Krol, Stephen W Potter and Susan B Washer.
View institutional ownership trends
.

How do I buy shares of Applied Genetic Technologies?

Shares of AGTC stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Applied Genetic Technologies' stock price today?

One share of AGTC stock can currently be purchased for approximately $0.38.

How much money does Applied Genetic Technologies make?

Applied Genetic Technologies (NASDAQ:AGTC) has a market capitalization of $25.36 million and generates $320,000.00 in revenue each year. The biotechnology company earns $-68,940,000.00 in net income (profit) each year or ($1.46) on an earnings per share basis.

How can I contact Applied Genetic Technologies?

Applied Genetic Technologies' mailing address is 14193 NW 119TH TERRACE SUITE 10, ALACHUA FL, 32615. The official website for the company is www.agtc.com. The biotechnology company can be reached via phone at (386) 462-2204 or via email at david.carey@finnpartners.com.

This page (NASDAQ:AGTC) was last updated on 11/29/2022 by MarketBeat.com Staff